专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008124000A3 THIAZOLE DERIVATIVES AS ANDROGEN RECEPTOR MODULATOR COMPOUNDS 审中-公开
标题翻译：作为雄激素受体调节剂化合物的噻唑衍生物
公开(公告)号：WO2008124000A3
公开(公告)日：2009-04-02
申请号：PCT/US2008004287
申请日：2008-04-01
申请人： LIGAND PHARM INC , ZHI LIN , KALLEL E ADAM , NGUYEN BAO NGOC , ADAMS MARK E , SHEN YIXING , LAU THOMAS LOT STEVENS , CHEN JYUN-HUNG , TYHONAS JOHN S , ARDECKY ROBERT J , MILLER TODD A , LOREN JON C
发明人： ZHI LIN , KALLEL E ADAM , NGUYEN BAO NGOC , ADAMS MARK E , SHEN YIXING , LAU THOMAS LOT STEVENS , CHEN JYUN-HUNG , TYHONAS JOHN S , ARDECKY ROBERT J , MILLER TODD A , LOREN JON C
IPC分类号： C07D277/46 , A61K31/426 , A61K31/427 , A61K31/4439 , A61P5/26 , C07D417/04 , C07D417/12 , C07D495/04
CPC分类号： C07D277/46 , C07D417/04 , C07D417/12 , C07D495/04
摘要： Provided herein are compounds of formula (I), (II), (III) or (IV) that bind to androgen receptors and/or modulate activity of androgen receptors and/or modulate the amount of androgen receptors and/or reduce the number of androgen receptors in a cell and/or degrade androgen receptors in a cell; and to methods for making and using such compounds. Also provided are compositions containing such compounds and methods for making and using such compositions.
摘要翻译：本文提供了结合雄激素受体和/或调节雄激素受体活性和/或调节雄激素受体量和/或减少雄激素受体数量的式（I），（II），（III）或（IV）细胞中的雄激素受体和/或降解细胞中的雄激素受体; 以及制备和使用这些化合物的方法。还提供含有这些化合物的组合物和制备和使用这些组合物的方法。

2. 发明专利

ES2353805T3 COMPUESTOS Y PROCEDIMIENTOS PARA MODULAR LA ACTIVIDAD DE LA TROMBOPOYETINA. 未知
公开(公告)号：ES2353805T3
公开(公告)日：2011-03-07
申请号：ES05813834
申请日：2005-10-21
申请人： LIGAND PHARM INC
发明人： CHEN JYUN-HUNG , DALGARD JACKLINE E , KALLEL ADAM E , LAU THOMAS , MCNEILL MATTHEW H , MILLER TODD A , NGUYEN BAO N , PENULAIR RICHARD J , PHILLIPS DEAN P , RUPPAR DANIEL A , ZHI LIN
IPC分类号： C07D277/54 , A61K31/404 , A61K31/426 , A61K31/472 , A61P7/00 , C07D209/40 , C07D217/24 , C07D239/60 , C07D405/04 , C07D409/04 , C07D417/12
摘要： Un compuesto de la fórmula III: **(Ver fórmula)** o una sal, éster, amida, o profármaco, de éstos, farmacéuticamente aceptables,en donde, R1, se selecciona de entre CO2R10, CONR10R11, SO3R10, y un bioisóstero de ácido carboxílico, seleccionado de entre tetrazol, NHSO2R15, OC(S)NR10R11, y **(Ver fórmula)** en donde,A, B y C, se seleccionan cada una de ellas, de una forma independiente, de entre O, S, y N; R2 y R3, se seleccionan, cada una de ellas, de una forma independiente, de entre null, hidrógeno, OR12, NR12R13, un alifático C1-4, opcionalmente sustituido, un haloalifático C1-C4, opcionalmente sustituido, un heteroalifático C1-C4, opcionalmente sustituido, un anillo, opcionalmente sustituido, y (CH2)mR14; ó R2 y R3, tomadas conjuntamente, forman una olefina, opcionalmente sustituida; ó R2 y R3, se encuentran unidas, para formar un anillo C3-C4, opcionalmente sustituido; R4, se selecciona de entre hidrógeno, F, Cl, Br, alifático C1-C4, haloalifático C1-C4, heteroalifático C1-C4, y un anillo; R5, se selecciona de entre hidrógeno, OR10, SR10, NHR11, y CO2H; R6, se selecciona de entre hidrógeno, OR12, NR12R13, F, Cl, Br, alquilo C1-C4; haloalquilo C1-C4, y heteroalquilo C1-C4; R7, se selecciona de entre hidrógeno, un alifático C1-C8, opcionalmente sustituido, un haloalifático C1-C8, opcionalmente sustituido, un heteroalifático C1-C8, opcionalmente sustituido, un heterohaloalifático C1-C8, opcionalmente sustituido, un anillo, opcionalmente sustituido, y (CH2)mR14; R8 y R9, se seleccionan, de una forma independiente, de entre hidrógeno, F, Cl, Br, CO2R10, NO2, CN, SO2R10, (CH2)mR14, alifático C1-C4, haloalifático C1-C4, heteroalifático C1-C4, y heterohaloalifático C1-C4; R10, se selecciona de entre hidrógeno, un alifático C1-C4, opcionalmente sustituido, haloalifático C1-C4, opcionalmente sustituido, heteroalifático C1-C4, opcionalmente sustituido, y un anillo; R11, se selecciona de entre hidrógeno, SO2R15, alifático C1-C4, haloalifático C1-C4, heteroalifático C1-C4, y un anillo; R12 y R13, se seleccionan, cada una de ellas, de una forma independiente, de entre hidrógeno, un alifático C1-4, opcionalmente sustituido, un haloalifático C1-C4, opcionalmente sustituido, un heteroalifático C1-C4, opcionalmente sustituido, un anillo, opcionalmente sustituido, y (CH2)mR14; ó una de las R12 y R13, es un alifático C2-C6, opcionalmente sustituido, ó un anillo, opcionalmente sustituido, y la otra de las R12 ó R13, es null; ó R12 y R13, se encuentran unidas, para formar un anillo C3-C8, opcionalmente sustituido; R14, se selecciona de entre un arilo, opcionalmente sustituido, y un heteroarilo, opcionalmente sustituido; R15, se selecciona de entre hidrógeno, un alifático C1-C3, un haloalifático C1-C3, y un anillo; m, es 0, 1, ó 2; y n, es 0 ó 1.

3. 发明专利

AU2005299720B2 Thrombopoietin activity modulating compounds and methods 未知
公开(公告)号：AU2005299720B2
公开(公告)日：2010-02-04
申请号：AU2005299720
申请日：2005-10-21
申请人： LIGAND PHARM INC
发明人： CHEN JYUN-HUNG , PHILLIPS DEAN P , NGUYEN BAO N , MCNEILL MATTHEW H , KALLEL ADAM E , DALGARD JACKLINE E , MILLER TODD A , ZHI LIN , PENULAIR RICHARD J , RUPPAR DANIEL A , LAU THOMAS
IPC分类号： C07D277/54 , A61K31/404 , A61K31/426 , A61K31/472 , A61P7/00 , C07D209/40 , C07D217/24 , C07D239/60 , C07D405/04 , C07D409/04 , C07D417/12
摘要： Disclosed herein are compounds of Formula (I), (II), and (III) pharmaceutical compositions comprising the same, methods of modulating the activity a thrombopoietin receptor using the same, methods of identifying compounds as thrombopoietin receptor modulators, and methods of treating disease by administering a compound of the invention to a patient in need thereof.

4. 发明专利

CA2583764C THROMBOPOIETIN ACTIVITY MODULATING COMPOUNDS AND METHODS 未知
公开(公告)号：CA2583764C
公开(公告)日：2009-06-09
申请号：CA2583764
申请日：2005-10-21
申请人： LIGAND PHARM INC
发明人： MCNEILL MATTHEW H , ZHI LIN , MILLER TODD A , CHEN JYUN-HUNG , LAU THOMAS , NGUYEN BAO N , KALLEL E ADAM , RUPPAR DANIEL A , PENULIAR RICHARD J , DALGARD JACKLINE E , PHILLIPS DEAN P
IPC分类号： C07D209/40 , A61K31/404 , A61K31/405 , A61K31/4178 , A61K31/426 , A61K31/427 , A61K31/4439 , A61K31/472 , A61K31/513 , A61P7/00 , C07D217/24 , C07D239/60 , C07D277/54 , C07D401/04 , C07D403/12 , C07D405/04 , C07D407/04 , C07D409/04 , C07D413/12 , C07D417/12 , C07D471/04
摘要： Disclosed herein are substituted arylhydrazino compounds, pharmaceutical compositions comprising the same, methods of modulating the activity a thrombopoietin receptor using the same, methods of identifying compounds as thrombopoietin receptor modulators, and methods of treating disease by administering a compound of the invention to a patient in need thereof.

5. 发明专利

AU2005299720A1 Thrombopoietin activity modulating compounds and methods 未知
公开(公告)号：AU2005299720A1
公开(公告)日：2006-05-04
申请号：AU2005299720
申请日：2005-10-21
申请人： LIGAND PHARM INC
发明人： CHEN JYUN-HUNG , PHILLIPS DEAN P , NGUYEN BAO N , MCNEILL MATTHEW H , KALLEL ADAM E , DALGARD JACKLINE E , MILLER TODD A , ZHI LIN , PENULAIR RICHARD J , RUPPAR DANIEL A , LAU THOMAS
IPC分类号： C07D277/54 , A61K31/404 , A61K31/426 , A61K31/472 , A61P7/00 , C07D209/40 , C07D217/24 , C07D239/60 , C07D405/04 , C07D409/04 , C07D417/12
摘要： Disclosed herein are compounds of Formula (I), (II), and (III) pharmaceutical compositions comprising the same, methods of modulating the activity a thrombopoietin receptor using the same, methods of identifying compounds as thrombopoietin receptor modulators, and methods of treating disease by administering a compound of the invention to a patient in need thereof.

6. 发明申请

WO2006031630A3 METHOD AND APPARATUS FOR RADIANT TUBE COMBUSTION 审中-公开
标题翻译：辐射管燃烧的方法和装置
公开(公告)号：WO2006031630A3
公开(公告)日：2006-10-26
申请号：PCT/US2005032077
申请日：2005-09-09
申请人： NORTH AMERICAN MFG COMPANY LTD , MILLER TODD A , QUINN DENNIS E , ROBERTSON THOMAS F
发明人： MILLER TODD A , QUINN DENNIS E , ROBERTSON THOMAS F
IPC分类号： F23M3/00 , F23M3/02 , F23M3/04
CPC分类号： F23C9/00 , F23C3/002 , F23C6/045 , F23C2201/20 , F23C2202/30
摘要： A method and apparatus provide combustion in a radiant tube in first, second and third stages, with flue gas recirculation that begins at the second stage.
摘要翻译：一种方法和装置在第一，第二和第三阶段的辐射管中提供燃烧，其中烟道气再循环从第二阶段开始。

7. 发明申请

WO0164681A2 3-(PYROLYLLACTONE)-2-INDOLINONE COMPOUNDS AS KINASE INHIBITORS 审中-公开
标题翻译： 3-（吡咯烷酮）-2-吲哚啉酮化合物作为激酶抑制剂
公开(公告)号：WO0164681A2
公开(公告)日：2001-09-07
申请号：PCT/US0106214
申请日：2001-02-28
申请人： SUGEN INC , TANG PENG CHO , MILLER TODD A , LI XIAOYUAN , ZHANG RUOFEI , CUI JINGRONG , HUANG PING , WEI CHUNG CHEN
发明人： TANG PENG CHO , MILLER TODD A , LI XIAOYUAN , ZHANG RUOFEI , CUI JINGRONG , HUANG PING , WEI CHUNG CHEN
IPC分类号： C07D491/052 , A61K31/407 , A61K31/437 , A61K31/4439 , A61K31/4709 , A61K31/4725 , A61K31/5377 , A61P1/00 , A61P11/00 , A61P13/08 , A61P13/10 , A61P15/00 , A61P17/00 , A61P25/00 , A61P35/00 , A61P43/00 , C07D471/04 , C07D491/04 , C07D491/044 , C07D519/00
CPC分类号： C07D471/04 , C07D491/04
摘要： The invention relates to certain indolinone compounds of formula (I), their method of synthesis, and a combinatorial library consisting of the indolinone compounds of the invention. The invention also relates to methods of modulating the function of protein kinases using indolinone compounds of the invention and methods of treating diseases by modulating the function of protein kinases and related signal transduction pathways.
摘要翻译：本发明涉及某些式（I）的吲哚满酮化合物，其合成方法和由本发明的二氢吲哚酮化合物组成的组合文库。本发明还涉及使用本发明的吲哚啉酮化合物调节蛋白激酶的功能的方法以及通过调节蛋白激酶和相关信号转导途径的功能来治疗疾病的方法。

8. 发明专利

DE602005024599D1 VERBINDUNGEN MODULIERENDE THROMBOPOIETINAKTIVITÄT UND VERFAHREN 未知
公开(公告)号：DE602005024599D1
公开(公告)日：2010-12-16
申请号：DE602005024599
申请日：2005-10-21
申请人： LIGAND PHARM INC
发明人： CHEN JYUN-HUNG , DALGARD JACKLINE E , KALLEL ADAM E , LAU THOMAS , MCNEILL MATTHEW H , MILLER TODD A , NGUYEN BAO N , PENULAIR RICHARD J , PHILLIPS DEAN P , RUPPAR DANIEL A , ZHI LIN
IPC分类号： C07D277/54 , A61K31/404 , A61K31/426 , A61K31/472 , A61P7/00 , C07D209/40 , C07D217/24 , C07D239/60 , C07D405/04 , C07D409/04 , C07D417/12

9. 发明专利

NO20072199L 未知
公开(公告)号：NO20072199L
公开(公告)日：2007-06-05
申请号：NO20072199
申请日：2007-04-27
申请人： LIGAND PHARM INC
发明人： CHEN JYUN-HUNG , DALGARD JACKLINE E , KALLEL ADAM E , LAU THOMAS , MCNEILL MATTHEW H , MILLER TODD A , NGUYEN BAO , PENULAIR RICHARD J , PHILLIPS DEAN P , RUPPAR DANIEL A , ZHI LIN
IPC分类号： C07D209/40 , A61K31/404 , A61P7/00
摘要： Disclosed herein are compounds of Formula (I), (II), and (III) pharmaceutical compositions comprising the same, methods of modulating the activity a thrombopoietin receptor using the same, methods of identifying compounds as thrombopoietin receptor modulators, and methods of treating disease by administering a compound of the invention to a patient in need thereof.

10. 发明专利

AT486859T 未知
公开(公告)号：AT486859T
公开(公告)日：2010-11-15
申请号：AT05813834
申请日：2005-10-21
申请人： LIGAND PHARM INC
发明人： CHEN JYUN-HUNG , DALGARD JACKLINE E , KALLEL ADAM E , LAU THOMAS , MCNEILL MATTHEW H , MILLER TODD A , NGUYEN BAO N , PENULAIR RICHARD J , PHILLIPS DEAN P , RUPPAR DANIEL A , ZHI LIN
IPC分类号： C07D277/54 , A61K31/404 , C07D209/40 , C07D217/24 , C07D239/60 , C07D405/04 , C07D409/04 , C07D417/12
摘要： Disclosed herein are compounds of Formula (I), (II), and (III) pharmaceutical compositions comprising the same, methods of modulating the activity a thrombopoietin receptor using the same, methods of identifying compounds as thrombopoietin receptor modulators, and methods of treating disease by administering a compound of the invention to a patient in need thereof.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式